Tenofovir Rectal Douche to Prevent HIV Transmission Among Adolescents (ATN DREAM)
Status:
Recruiting
Trial end date:
2022-07-01
Target enrollment:
Participant gender:
Summary
ATN DREAM is an early phase-1, open label study to examine the safety, pharmacokinetics (PK),
pharmacodynamics (PD), and acceptability of a one-dose tenofovir (TFV) medicated douche. The
overall goal is to inform the design of an extended safety study of an on-demand and
behaviorally congruent TFV douche to confer protection from HIV acquisition in an outpatient
pre-RAI context
Phase:
Phase 1
Details
Lead Sponsor:
University of Pennsylvania
Collaborators:
Emory University Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) Johns Hopkins University University of North Carolina, Chapel Hill